DBV Technologies SA – (DBVT) Sees Large Increase in Short Interest
DBV Technologies SA – (NASDAQ:DBVT) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,239,316 shares, a growth of 28.3% from the February 15th total of 966,186 shares. Based on an average daily trading volume, of 520,947 shares, the short-interest ratio is presently 2.4 days.
A number of institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new position in DBV Technologies in the third quarter valued at approximately $132,000. Quantbot Technologies LP purchased a new position in DBV Technologies in the third quarter valued at approximately $146,000. Geode Capital Management LLC increased its stake in DBV Technologies by 20.2% in the fourth quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock valued at $512,000 after purchasing an additional 3,499 shares during the last quarter. Alps Advisors Inc. increased its stake in DBV Technologies by 9.1% in the third quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock valued at $2,015,000 after purchasing an additional 3,964 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its stake in DBV Technologies by 87.6% in the third quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock valued at $495,000 after purchasing an additional 5,441 shares during the last quarter. Institutional investors own 45.72% of the company’s stock.
A number of analysts recently weighed in on DBVT shares. Citigroup set a $57.00 target price on shares of DBV Technologies and gave the stock a “buy” rating in a research note on Wednesday, February 14th. BidaskClub upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. JMP Securities began coverage on shares of DBV Technologies in a research note on Friday, November 17th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Monday, December 25th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. DBV Technologies currently has a consensus rating of “Hold” and an average target price of $49.63.
WARNING: “DBV Technologies SA – (DBVT) Sees Large Increase in Short Interest” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/03/14/dbv-technologies-sa-dbvt-sees-large-increase-in-short-interest.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.